cebranopadol (TRN-228) - Tris Pharma
A Study to Assess the Abuse Potential of Intranasal Cebranopadol (clinicaltrials.gov) - Jun 11, 2024 - P1 | N=45 | Not yet recruiting | Sponsor: Tris Pharma, Inc. 
New P1 trial • Addiction (Opioid and Alcohol)
http://clinicaltrials.gov/ct2/show/NCT06453265
 
Jun 11, 2024
 
Prev Next